332 related articles for article (PubMed ID: 36232561)
21. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
Berg D
Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
[TBL] [Abstract][Full Text] [Related]
23. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
24. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
25. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin.
Lila AS; Kiwada H; Ishida T
Biol Pharm Bull; 2014; 37(2):206-11. PubMed ID: 24492717
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
27. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
28. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
29. Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?
Sagar J; Sales K; Dijk S; Taanman J; Seifalian A; Winslet M
World J Surg Oncol; 2009 Jan; 7():2. PubMed ID: 19126215
[TBL] [Abstract][Full Text] [Related]
30. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
31. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
32. [Oxaliplatin: a first DACH-platinum in oncology].
Laadem A; Cvitkovic E
Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
[TBL] [Abstract][Full Text] [Related]
33. Recent Developments in the Field of Anticancer Platinum Complexes.
Galanski MS
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):285-95. PubMed ID: 18221042
[TBL] [Abstract][Full Text] [Related]
34. Curcumin-enhanced chemosensitivity of FDA-approved platinum (II)-based anti-cancer drugs involves downregulation of nuclear endonuclease G and NF-κB as well as induction of apoptosis and G2/M arrest.
Wang YT; Liu HS; Su CL
Int J Food Sci Nutr; 2014 May; 65(3):368-74. PubMed ID: 24438326
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
36. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
37. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
Kusumoto T; Holden SA; Ara G; Teicher BA
Int J Hyperthermia; 1995; 11(4):575-86. PubMed ID: 7594810
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.
Becker JP; Weiss J; Theile D
Toxicol Lett; 2014 Feb; 225(1):43-7. PubMed ID: 24275384
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
40. Review of oxaliplatin: an active platinum agent in colorectal cancer.
Cassidy J
Int J Clin Pract; 2000; 54(6):399-402. PubMed ID: 11092115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
